Analyst Sean Lee CFA of H.C. Wainwright maintained a Buy rating on Monopar Therapeutics Inc (MNPR – Research Report), boosting the price ...
H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $22 from $6 and keeps a Buy rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback